Repaglinide

From WikiMD's WELLNESSPEDIA

(Redirected from Enyglid)

Repaglinide
Repaglinide ball-and-stick model

Information about Repaglinide[edit]

Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes.

Liver safety of Repaglinide[edit]

Repaglinide has been linked to rare instances of clinically apparent acute liver injury.

Mechanism of action of Repaglinide[edit]

Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with type 2 diabetes and improve glycemic control. Repaglinide

FDA approval information for Repaglinide[edit]

Repaglinide was approved for use in the United States in 1997. The current indications are for management of type 2 diabetes used in combination with diet and exercise, with or without other oral hypoglycemic agents.

Brand name for Repaglinide[edit]

Repaglinide is available generically and under the brand name Prandin in tablets of 0.5, 1 and 2 mg.

Dosage and administration for Repaglinide[edit]

The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.

Side effects of Repaglinide[edit]

Side effects of repaglinide include diarrhea, nausea, gastrointestinal upset, hypoglycemia, headache, dizziness, arthralgia and rash. Antidiabetics 

 Oral diabetes medication, insulins and insulin analogs, and other drugs used in diabetes (A10)


fast-acting
short-acting
long-acting
ultra-long-acting
inhalable
* Exubera‡
  • Afrezza



Insulin sensitizers
Secretagogues
Other
Combinations








Template:Ion channel modulators

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Repaglinide&oldid=6532097"